U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
Go back to U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 51.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.08 | 52 Week High | $45.58 | |||
| Open | $51.08 | 52 Week Low | $37.82 | |||
| Day High | $51.08 | P/E | N/A | |||
| Day Low | $51.08 | EPS | $0.00 | |||
| Volume | 4,597 | |||||
